These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 28059436)

  • 1. The BET Bromodomain Inhibitor JQ1 Suppresses Chondrosarcoma Cell Growth via Regulation of YAP/p21/c-Myc Signaling.
    Zhang HT; Gui T; Sang Y; Yang J; Li YH; Liang GH; Li T; He QY; Zha ZG
    J Cell Biochem; 2017 Aug; 118(8):2182-2192. PubMed ID: 28059436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential targeting of YAP1 and p21 enhances the elimination of senescent cells induced by the BET inhibitor JQ1.
    Zhang HT; Gui T; Liu RX; Tong KL; Wu CJ; Li Z; Huang X; Xu QT; Yang J; Tang W; Sang Y; Liu W; Liu N; Ross RD; He QY; Zha ZG
    Cell Death Dis; 2021 Jan; 12(1):121. PubMed ID: 33495462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of BET bromodomain targets genetically diverse glioblastoma.
    Cheng Z; Gong Y; Ma Y; Lu K; Lu X; Pierce LA; Thompson RC; Muller S; Knapp S; Wang J
    Clin Cancer Res; 2013 Apr; 19(7):1748-59. PubMed ID: 23403638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of FOXO1 expression.
    Tan Y; Wang L; Du Y; Liu X; Chen Z; Weng X; Guo J; Chen H; Wang M; Wang X
    Int J Oncol; 2018 Dec; 53(6):2503-2517. PubMed ID: 30272279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth in vivo.
    Shao Q; Kannan A; Lin Z; Stack BC; Suen JY; Gao L
    Cancer Res; 2014 Dec; 74(23):7090-102. PubMed ID: 25277525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer.
    Bagratuni T; Mavrianou N; Gavalas NG; Tzannis K; Arapinis C; Liontos M; Christodoulou MI; Thomakos N; Haidopoulos D; Rodolakis A; Kastritis E; Scorilas A; Dimopoulos MA; Bamias A
    Eur J Cancer; 2020 Feb; 126():125-135. PubMed ID: 31927213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer.
    Enomoto K; Zhu X; Park S; Zhao L; Zhu YJ; Willingham MC; Qi J; Copland JA; Meltzer P; Cheng SY
    J Clin Endocrinol Metab; 2017 Jul; 102(7):2268-2280. PubMed ID: 28368473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors.
    Tolani B; Gopalakrishnan R; Punj V; Matta H; Chaudhary PM
    Oncogene; 2014 May; 33(22):2928-37. PubMed ID: 23792448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting c-Myc: JQ1 as a promising option for c-Myc-amplified esophageal squamous cell carcinoma.
    Wang J; Liu Z; Wang Z; Wang S; Chen Z; Li Z; Zhang M; Zou J; Dong B; Gao J; Shen L
    Cancer Lett; 2018 Apr; 419():64-74. PubMed ID: 29366803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model.
    Zhu X; Enomoto K; Zhao L; Zhu YJ; Willingham MC; Meltzer P; Qi J; Cheng SY
    Clin Cancer Res; 2017 Jan; 23(2):430-440. PubMed ID: 27440272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bromodomains and Extra-Terminal (BET) Inhibitor JQ1 Suppresses Proliferation of Acute Lymphocytic Leukemia by Inhibiting c-Myc-Mediated Glycolysis.
    Zhang MY; Liu SL; Huang WL; Tang DB; Zheng WW; Zhou N; Zhou H; Abudureheman T; Tang ZH; Zhou BS; Duan CW
    Med Sci Monit; 2020 Apr; 26():e923411. PubMed ID: 32266878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BET bromodomain inhibitor JQ1 decreases CD30 and CCR4 expression and proliferation of cutaneous T-cell lymphoma cell lines.
    Kamijo H; Sugaya M; Takahashi N; Oka T; Miyagaki T; Asano Y; Sato S
    Arch Dermatol Res; 2017 Aug; 309(6):491-497. PubMed ID: 28593508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
    Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
    Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BET bromodomain inhibition of MYC-amplified medulloblastoma.
    Bandopadhayay P; Bergthold G; Nguyen B; Schubert S; Gholamin S; Tang Y; Bolin S; Schumacher SE; Zeid R; Masoud S; Yu F; Vue N; Gibson WJ; Paolella BR; Mitra SS; Cheshier SH; Qi J; Liu KW; Wechsler-Reya R; Weiss WA; Swartling FJ; Kieran MW; Bradner JE; Beroukhim R; Cho YJ
    Clin Cancer Res; 2014 Feb; 20(4):912-25. PubMed ID: 24297863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members.
    Hogg SJ; Newbold A; Vervoort SJ; Cluse LA; Martin BP; Gregory GP; Lefebure M; Vidacs E; Tothill RW; Bradner JE; Shortt J; Johnstone RW
    Mol Cancer Ther; 2016 Sep; 15(9):2030-41. PubMed ID: 27406984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compensatory RNA polymerase 2 loading determines the efficacy and transcriptional selectivity of JQ1 in Myc-driven tumors.
    Donato E; Croci O; Sabò A; Muller H; Morelli MJ; Pelizzola M; Campaner S
    Leukemia; 2017 Feb; 31(2):479-490. PubMed ID: 27443262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells.
    Tögel L; Nightingale R; Chueh AC; Jayachandran A; Tran H; Phesse T; Wu R; Sieber OM; Arango D; Dhillon AS; Dawson MA; Diez-Dacal B; Gahman TC; Filippakopoulos P; Shiau AK; Mariadason JM
    Mol Cancer Ther; 2016 Jun; 15(6):1217-26. PubMed ID: 26983878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer.
    Qiu H; Li J; Clark LH; Jackson AL; Zhang L; Guo H; Kilgore JE; Gehrig PA; Zhou C; Bae-Jump VL
    Oncotarget; 2016 Oct; 7(41):66809-66821. PubMed ID: 27572308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
    Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
    Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma.
    Lee DH; Qi J; Bradner JE; Said JW; Doan NB; Forscher C; Yang H; Koeffler HP
    Int J Cancer; 2015 May; 136(9):2055-64. PubMed ID: 25307878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.